Read by QxMD icon Read

Atrial fibrilation and cancer

Konstantinos A Toulis, David Viola, George Gkoutos, Deepiksana Keerthy, Kristien Boelaert, Krishnarajah Nirantharakumar
CONTEXT: The incidence of differentiated thyroid cancer (DTC) is increasing, yet the prognosis is favorable and long-term survival is expected. Exogenous TSH suppression has been used for many years to prevent DTC recurrence and may be associated with increased risks of circulatory diseases. DESIGN: Risks of circulatory disease in patients treated for DTC were compared to randomly matched patients without DTC (controls) up to a 1:5 ratio using age, sex, body mass index (BMI) and smoking as the matching parameters in a population-based, open cohort study using The Health Improvement Network...
April 16, 2019: Clinical Endocrinology
Pablo Garcia-Pavia, Yuri Kim, Maria Alejandra Restrepo-Cordoba, Ida G Lunde, Hiroko Wakimoto, Amanda M Smith, Christopher N Toepfer, Kelly Getz, Joshua Gorham, Parth Patel, Kaoru Ito, Jonathan A Willcox, Zoltan Arany, Jian Li, Anjali T Owens, Risha Govind, Beatriz Nuñez, Erica Mazaika, Antoni Bayes-Genis, Roddy Walsh, Brian Finkelman, Josep Lupon, Nicola Whiffin, Isabel Serrano, William Midwinter, Alicja Wilk, Alfredo Bardaji, Nathan Ingold, Rachel Buchan, Upasana Tayal, Domingo A Pascual-Figal, Antonio de Marvao, Mian Ahmad, Jose Manuel Garcia-Pinilla, Antonis Pantazis, Fernando Dominguez, A John Baksi, Declan P O'Regan, Stuart D Rosen, Sanjay K Prasad, Enrique Lara-Pezzi, Mariano Provencio, Alexander R Lyon, Luis Alonso-Pulpon, Stuart A Cook, Steven R DePalma, Paul J R Barton, Richard Aplenc, Jonathan G Seidman, Bonnie Ky, James S Ware, Christine E Seidman
BACKGROUND: Cancer therapy-induced cardiomyopathy (CCM) is associated with cumulative drug exposures and pre-existing cardiovascular disorders. These parameters incompletely account for substantial inter-individual susceptibility to CCM. We hypothesized that rare variants in cardiomyopathy genes contribute to CCM. METHODS: We studied 213 CCM patients from three cohorts: retrospectively recruited adults with diverse cancers (n=99), prospectively phenotyped breast cancer adults (n=73) and prospectively phenotyped children with acute myeloid leukemia (n=41)...
April 16, 2019: Circulation
Dhrubajyoti Bandyopadhyay, Somedeb Ball, Adrija Hajra, Sandipan Chakraborty, Amit Kumar Dey, Raktim K Ghosh, Angela M Palazzo
No abstract text is available yet for this article.
March 2019: IJC Heart & Vasculature
Hirotsugu Hashimoto, Genki Usui, Yuta Tsugeno, Keisuke Sugita, Gulanbar Amori, Teppei Morikawa, Kentaro Inamura
Lung cancer is the leading cause of cancer-related deaths worldwide. Although molecular therapies have emerged as efficacious strategies for the treatment of lung cancer, surgical resection is still recommended as a radical therapeutic option. Currently, lobectomy is regarded as the most reliable radical treatment of primary lung cancer. Among the various complications after lobectomy, cerebral thromboembolism requires attention as a life-threatening complication during the early postoperative period. It occurs in 0...
April 5, 2019: Cancers
Hooman Kamel, Alexander E Merkler, Costantino Iadecola, Ajay Gupta, Babak B Navi
Importance: One-third of ischemic strokes have no identifiable cause after standard evaluation. In 2014, researchers termed these embolic strokes of undetermined source (ESUS) and argued that this entity would respond to anticoagulation. Two recent randomized clinical trials have not upheld this hypothesis, leading to questions about the ESUS concept. Observations: This article proposes that ESUS remains a useful concept, the clinical effect of which can be enhanced by considering 2 subsets defined by their likelihood of responding to anticoagulation...
April 8, 2019: JAMA Neurology
Isaac B Rhea, Alexander R Lyon, Michael G Fradley
PURPOSE OF REVIEW: The anticoagulation strategies for various cardiac-specific pathologies including atrial fibrillation are changing. Applying these strategies in patients with concomitant active cancer requires additional considerations. Here, we review the most recent changes in the anticoagulation management of common cardiac diseases and their application in cancer patients. RECENT FINDINGS: There are a range of indications for therapeutic anticoagulation in cancer patients including venous thromboembolism (VTE), atrial fibrillation/flutter (AF/AFL), prosthetic heart valves, and intracardiac thrombi...
April 4, 2019: Current Oncology Reports
Rindo Ishii, Eiji Sakai, Kentarou Nakajima, Nobuyuki Matsuhashi, Ken Ohata
Although conventional bowel preparation for colonoscopy rarely causes serious complications, such complications can be fatal and, therefore, require early recognition and prompt treatment. Herein, we report a case of non-occlusive mesenteric ischemia (NOMI) induced by polyethylene glycol with an ascorbate component (PEG + Asc) that was used as a colonic bowel preparation. An- 82-year-old woman with a medical history of hypertension, atrial fibrillation and mild chronic renal failure received a cancer screening colonoscopy...
April 1, 2019: Clinical Journal of Gastroenterology
Kevin J O'Gorman, Tyson J Sjulin, Donnell K Bowen, Michael J Morris
Pulmonary vein stenosis (PVS) is a serious complication of radiofrequency ablation (RFA) for the treatment of atrial fibrillation. The prevalence of this complication was reported to be as high as 42% in 1999 when RFA was first implemented [1]. However, with improvements in operator technique including wide area circumferential ablation, antral isolation, and the use of intracardiac ultrasound, the incidence of symptomatic severe PVS following RFA ranges from 0% to 2.1% while the incidence of symptomatic pulmonary vein occlusion (PVO) following RFA was found to be 0...
2019: Respiratory Medicine Case Reports
Rossella Martinello, Paolo Becco, Patrizia Vici, Mario Airoldi, Lucia Del Mastro, Ornella Garrone, Carla Barone, Laura Pizzuti, Alessia D'Alonzo, Elisa Bellini, Andrea Milani, Alessandro Bonzano, Filippo Montemurro
BACKGROUND: Significant and symptomatic cardiac comorbidity is a contraindication to adjuvant trastuzumab in breast cancer patients. However, some patients with asymptomatic, nonlimiting cardiac comorbidity and normal baseline left ventricular ejection fraction (LVEF) receive adjuvant trastuzumab in the clinical practice. We sought to describe the tolerability of trastuzumab in these patients. PATIENTS AND METHODS: Retrospective analysis of patients with baseline asymptomatic, nonlimiting cardiac comorbidity receiving adjuvant trastuzumab at six Institutions between July 2007 and January 2016...
April 1, 2019: Breast Journal
Gordon Chu, Henri H Versteeg, Arie J Verschoor, Serge A Trines, Martin E W Hemels, Cihan Ay, Menno V Huisman, Frederikus A Klok
An increasing body of evidence suggests an association between cancer and atrial fibrillation (AF). The exact magnitude and underlying mechanism of this association are however unclear. Cancer-related inflammation, anti-cancer treatment and other cancer-related comorbidities are proposed to affect atrial remodelling, increasing the susceptibility of cancer patients for developing AF. Moreover, cancer is assumed to modify the risk of thromboembolisms and bleeding. A thorough and adequate understanding of these risks is however lacking, as current literature is scarce and show ambiguous results in AF patients...
March 25, 2019: Blood Reviews
D Schizas, M Kosmopoulos, S Giannopoulos, S Giannopoulos, D G Kokkinidis, N Karampetsou, C A Papanastasiou, I Rouvelas, T Liakakos
BACKGROUND: Oesophagectomy is associated with high morbidity and mortality rates. New-onset atrial fibrillation (AF) is a frequent complication following oesophagectomy. Several studies have explored whether new-onset AF is associated with adverse events after oesophagectomy. METHODS: This review was performed according to PRISMA guidelines. Eligible studies were identified through a search of PubMed, Scopus and Cochrane CENTRAL databases up to 25 November 2018...
April 2019: British Journal of Surgery
Man-Ling Wang, Ming-Hui Hung, Hsao-Hsun Hsu, Kuang-Cheng Chan, Ya-Jung Cheng, Jin-Shing Chen
Background: Patients with impaired lung function or chronic obstructive pulmonary disease (COPD) are considered high-risk for intubated general anesthesia, which may preclude them from surgical treatment of their lung cancers. We evaluated the feasibility of non-intubated video-assisted thoracoscopic surgery (VATS) for the surgical management of lung cancer in patients with impaired pulmonary function. Methods: From August 2009 to June 2015, 28 patients with impaired lung function (preoperative forced expiratory volume in 1 second <70% of the predicted value) underwent non-intubated VATS using a combination of thoracic epidural anesthesia or intercostal nerve block, and intra-thoracic vagal block with target-controlled sedation...
February 2019: Annals of Translational Medicine
Ramya C Mosarla, Muthiah Vaduganathan, Arman Qamar, Javid Moslehi, Gregory Piazza, Robert P Giugliano
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring...
March 26, 2019: Journal of the American College of Cardiology
Carlos Escobar Cervantes, José Luis Merino, Vivencio Barrios
Edoxaban is the last direct oral anticoagulant marketed for the prevention of stroke among patients with nonvalvular atrial fibrillation (AF). Areas covered: ENGAGE AF-TIMI 48 was the pivotal clinical trial that led to the approval of edoxaban 60 mg once daily. After the publication of this study, a great number of substudies and post hoc analyses have been published, together with some observational studies. The aim of this review was to update the current evidence about the use of edoxaban in AF patients...
March 21, 2019: Expert Review of Cardiovascular Therapy
Jun Tang, Jian-Zhu Zhao, Kai-Ming Ren, Fu-Shuang Zheng, Xi-Wen Wang, Hai-Jun Liu, Jun-Gang Zhao, Ji-Bin Lu
BACKGROUND: Atrial fibrillation (AF) is a common complication after radical surgery of esophageal cancer. The aim of this study was to explore AF risk factors after radical surgery of esophageal carcinoma. METHOD: The data of 335 patients with esophageal cancer who were admitted in our hospital from January 2014 to August 2016 for the first time were retrospectively analyzed. We retrieved the papers in some data banks using the search terms including English and Chinese search terms, and obtained 13 factors which were mentioned in more than 6 papers...
March 14, 2019: Journal of Cardiothoracic Surgery
Celal Bugra Sezen, Celalettin Ibrahim Kocaturk, Salih Bilen, Cem Emrah Kalafat, Cemal Aker, Kemal Karapinar
BACKGROUND: Completion pneumonectomy (CP) is the removal of remaining lung tissue after initial resection. Our aim in this study was to investigate the factors affecting mortality, morbidity, and survival after CP. METHODS: Patients who underwent CP in our clinic between January 2000 and December 2015 were evaluated retrospectively. The patients' demographic information, morbidity, mortality, histopathological characteristics, and 2-, 5-, and 10-year survival were evaluated...
March 1, 2019: Acta Chirurgica Belgica
Taku Yasui, Wataru Shioyama, Makiko Oboshi, Toru Oka, Masashi Fujita
Objective Oral anticoagulants (OACs), which include direct oral anticoagulants (DOACs) and warfarin, are widely used for the prevention of thromboembolic events in patients with atrial fibrillation (AF). Cancer is associated with a prothrombotic state as well as an increased bleeding risk. Few data are available on the efficacy and safety of OACs in Japanese cancer patients with AF. We sought to investigate the efficacy and safety of OACs in this population. Methods This retrospective cohort study included active cancer patients in whom AF was recorded by electrocardiography in our hospital from January 2014 to December 2016 and who were treated with DOACs or warfarin...
February 25, 2019: Internal Medicine
Lewis Steell, Frederick K Ho, Anne Sillars, Fanny Petermann-Rocha, Hiu Li, Donald M Lyall, Stamatina Iliodromiti, Paul Welsh, Jana Anderson, Daniel F MacKay, Jill P Pell, Naveed Sattar, Jason Mr Gill, Stuart Robert Gray, Carlos A Celis-Morales
OBJECTIVE: To investigate the association of cardiorespiratory fitness with all-cause mortality, and cardiovascular disease (CVD), respiratory disease, chronic obstructive pulmonary disease (COPD) and cancer mortality and incidence. DESIGN: Prospective population-based study. SETTING: UK Biobank. PARTICIPANTS: Of the 5 02 628 (5.5% response rate) participants recruited by UK Biobank, we included 73 259 (14.6%) participants with available data in this analysis...
February 22, 2019: British Journal of Sports Medicine
Giuseppe Patti, Alessandro Sticchi, Vincenzo Pasceri, Fabrizio Ricci, Giulia Renda, Viktor Hamrefors, Olle Melander, Richard Sutton, Gunnar Engström, Raffaele De Caterina, Artur Fedorowski
BACKGROUND: Risk factors included in the CHA2 DS2 -VASc score, currently used for atrial fibrillation (AF), may predispose to cardiovascular events whether or not AF is present. Aim was to explore the predictive role of CHA2 DS2 -VASc score on cardiovascular outcomes in diabetic patients without AF. METHODS: We accessed individual data from 610 diabetic patients without AF at baseline included in the prospective cohort of the Malmö Diet and Cancer Study. Main outcome measure was the occurrence of cardiovascular events (stroke, coronary events) and death...
February 21, 2019: Diabetes/metabolism Research and Reviews
Daisuke Kurita, Takeo Fujita, Yasumasa Horikiri, Takuji Sato, Hisashi Fujiwara, Hiroyuki Daiko
BACKGROUND: Non-occlusive mesenteric ischemia (NOMI) is a rare but life-threatening complication of early postoperative enteral feeding. We herein report two patients who developed NOMI during enteral feeding after esophagectomy. CASE PRESENTATION: In case 1, a 75-year-old man with no medical history was diagnosed with multiple primary cancers of the esophagus, stomach, and kidney. He underwent percutaneous endoscopic gastrostomy tube placement followed by thoracoscopic esophagectomy and cervical esophagostomy placement as the first-stage operation...
February 20, 2019: Surgical Case Reports
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"